chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This report describes the occurrence of mercury poisoning in a male child of unspecified age who was vaccinated with hep B vaccine recombinant (Engerix B) for prophylaxis. This report was received as part of litigation proceedings and has not been verified by a physician or other healthcare professional. The subject's medical history, concurrent conditions, and concurrent medications were not reported. The subject received an injection of Engerix B (lot 2499A2) on 3/9/98. He also received injections of hep B vaccine (manuf unk) 9/14/98, diphtheria and tetanus toxoids and pertussis vaccine (manuf unk) 5/8/98, 7/8/98 and 6/18/99, Tetramune 9/14/98 and haemoophilus influenzae type B conjugate vaccine (manuf unk) 6/18/99. The subject's attorney alleged that "As a result of the mercury in the Thimerosal-containing vaccinations that the subject received he now suffers, and in the future will continue to suffer, from the toxic neurological effects of mercury poisoning." The attorney further alleged that the subject "has developed severe neurodevelopmental disorders with associated high mercury exposure levels as a result of the vaccinations he received, and has suffered serious permanent injury." Onset and treatment of the events were not specified. The mercury poisoning in this report, with resultant neruodevelopmental disorders, is considered medically serious (OMIC).
a sore throat the next day and for two days sore throat and running nose.  next saturday hoarseness and slight shorness of breathing.  Today still slight hoarseness.
Redness, swelling, hot to touch, tender, painful.  3 inches in diameter at injection site
Three to four minutes after the Patient received the above vaccines, he became pale and diaphoretic and showed seizure like symptoms.
Patient experienced diarrhea after 3rd booster dose; Patient received 3 booster doses instead of 2 because she was immunocompromised; received 2 full shots of Moderna COVID-19 Vaccine and 3 booster doses after the primary series; This spontaneous case was reported by a patient and describes the occurrence of DIARRHOEA (Patient experienced diarrhea after 3rd booster dose), EXTRA DOSE ADMINISTERED (Patient received 3 booster doses instead of 2 because she was immunocompromised) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (received 2 full shots of Moderna COVID-19 Vaccine and 3 booster doses after the primary series) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     Concurrent medical conditions included Immunocompromised and Wegeners granulomatosis (Wegener's vasculitis).   On 04-Aug-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form, second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Aug-2022, the patient experienced DIARRHOEA (Patient experienced diarrhea after 3rd booster dose), EXTRA DOSE ADMINISTERED (Patient received 3 booster doses instead of 2 because she was immunocompromised) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (received 2 full shots of Moderna COVID-19 Vaccine and 3 booster doses after the primary series). At the time of the report, DIARRHOEA (Patient experienced diarrhea after 3rd booster dose), EXTRA DOSE ADMINISTERED (Patient received 3 booster doses instead of 2 because she was immunocompromised) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (received 2 full shots of Moderna COVID-19 Vaccine and 3 booster doses after the primary series) outcome was unknown.            Information about allergies was Unknown. It was reported that the patient was Immunocompromised and that was why she received 2 full doses of primary series and three booster doses after primary series to be protected. Patient received third dose of vaccine due to the condition of Wegener's vasculitis. No concomitant medications were reported. No treatment details were reported.   This case was linked to MOD-2022-624057 (Patient Link).   Reporter did not allow further contact
it was like having Covid again; it was like having Covid again; body aches; dry mouth; generalized weakness; temp was 38.1 Celsius; head feels weird; can't sleep; decreased appetite; pain at the injection site; This is a spontaneous report from a contactable Nurse (patient). A 36-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 04Jan2021 at single dose for COVID-19 immunization. Medical history included COVID-19 from Mar2020 to an unknown date.  The patient's concomitant medications were not reported. The patient experienced body aches, dry mouth, can't sleep, generalized weakness, decreased appetite, and pain at the injection site, temp was 38.1 Celsius, head feels weird in Jan2021. The patient got her first dose and was looking online to see the symptoms. She said that she saw that during the trials, people were experiencing the symptoms she was experiencing after the second dose and she was concerned. She said that she wanted to make sure her symptoms are ok and to make sure that the symptoms are not just caused from the booster, but also from the first dose. The caller said that her mom told her that someone died from the Pfizer vaccine. No further details provided. The patient was having body aches, could not sleep, her mouth is really dry, her temp was 38.1 Celsius, her head feels weird, she has generalized weakness, pain at the injection site, and decreased appetite. She said that it was like having Covid again. She said that she had Covid back in Mar2020. The patient underwent lab tests and procedures which included body temperature: 38.1 centigrade.  The outcome of all the events was unknown. The events were reported as non-serious. Information on the lot/batch number has been requested.; Sender's Comments: No effect of the suspect vaccine could be reasonably achieved to protect from the targeted infection/disease due to the very short time lag.  Instead, the suspected COVID likely represents a pre-existing infection prior to vaccine use.  Further information like confirmative COVID 19 Nucleic acid/ PCR test is needed for full medical assessment.
An 83 year old female patient had received an injection (Route and site not reported) of FLUZONE SV '2005-'2006 USP (lot number not reported), on 19/Oct/2005. Per the reported, one to two days later the patient complained of chills. Then 23/Oct/2005 her behavior changed drastically with mental changes and a change in her disposition. The patient suddenly became illogical and had memory loss along with anxiety and paranoia. The reporter described this with an example of the patient asking "Where is my mother in the house?" The patient did not recognize people close to her. The patient was not evaluated by a physician. The reporter states that the patient has had a similar reaction such as this in the past with the use of prednisone. Follow up information received on 15/Dec/2005 from the vaccine provider. Lot number for Fluzone SV 2005-2006 is provided as U1903AA. The vaccine provider is not the patients health care provider. Additional medical information cannot be provided for this patient. The patient is lost to follow up. Further information is not expected.
Left shoulder inflammation swelling pain prolonged 4 months left wrist swelling prolonged, right arm elbow joint swelling and pain prolonged. No arthritis or joint pains complaints prior to vaccine. post vaccine daily complaints of joint pain, limited mobility and swelling.
Swallow that appeared in his testicle/diagnosed with epididymitis; This spontaneous case was received on 11-Oct-2022 from nurse via Communications (reference number: SEQW22-04326) and concerned a 35-year-old, male patient.  The patient's medical history and concomitant medications were not reported.  On 05-Oct-2022, the patient was vaccinated with Afluria Quadrivalent (influenza vaccine inact split 4v; dose: 0.5 ml, route of administration: intramuscular, anatomical location: not reported) for influenza prophylaxis. The batch number was not reported.  On 06-Oct-2022, one day after receiving Afluria Quadrivalent, the patient complained about a swallow that appeared in his testicle. The patient went to the emergency department (ED), where an ultrasound was performed, and he was diagnosed with epididymitis. The patient was treated with Rocefin (ceftriaxone sodium), intramuscularly and Levaquin (levofloxacin), orally. The ED sent him home after treatment.  At the time of initial report on 11-Oct-2022, the patient had not recovered from the event.  The reporter did not provide a causality assessment.  The event of 'epididymitis' was assessed as serious due to seriousness criterion of medical significance.  Company comment: A 35-year-old patient developed epididymitis one day after receiving the suspect product Afluria Quadrivalent. The patient's medical history and concomitant drugs were not provided.  Based on biological implausibility, causal role of the suspect vaccine is assessed as not related.; Sender's Comments: A 35-year-old patient developed epididymitis one day after receiving the suspect product Afluria Quadrivalent. The patient's medical history and concomitant drugs were not provided.  Based on biological implausibility, causal role of the suspect vaccine is assessed as not related.
Right arm is swollen and hot. ER and urgent care was recommended to the patient. Not sure if patient will go. Pt will wait if the swelling is not she'll go to the ER/urgent care
Dose 3 of BNT162B2 and Infuenza vaccine on same date; Dose 3 of BNT162B2 and Infuenza vaccine on same date; Sore Left arm; headache; tiredness; sneezing; congestion; dry cough; low grade fever; chills; coughing turned slightly productive; This is a spontaneous report from a non-contactable physician (patient). A 62-years-old male patient received booster dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EW0161), via an unspecified route of administration, administered in left arm on 27Sep2021 (at the age of 62 years) as dose 3 (booster), single for COVID-19 immunization; and influenza vaccine inact split 4v (AFLURIA QUADRIVALENT) (Lot Number: P100350391), via an unspecified route of administration on right arm on 27Sep2021 as dose 1, single for immunisation. Medical history included hypertension, and secondary glaucoma L-eye, both from an unknown date and unknown if ongoing. Patient had corneal transplant - L eye on an unknown date. Concomitant medications received within two weeks of vaccination included losartan; timolol maleate (TIMOPTIC); and prednisolone (ophthalmic), all taken for an unspecified indication, start and stop date were not reported. Patient previously took first dose of bnt162b2 (Lot number: EK9231) on 23Dec2020 as dose 1, single and second dose of bnt162b2 (Lot number: EK4176) on 13Jan2021 as dose 2, single, both via an unspecified route of administration, administered in left arm, for COVID-19 immunization. Patient had no known allergies. No other vaccine in four weeks. Prior to vaccination, patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date in Sep2021, the patient experienced sore Left arm for first 24 hours of vaccination. About 24 hours after dose, patient experienced headache, tiredness, sneezing, congestion, and dry cough. Then after 24-48 hours, patient had low grade fever and chills. After 48-72 hours, patient had coughing turned slightly productive, sneezing, and congestion, Dose 3 of BNT162B2 and Infuenza vaccine on same date on 27Sep2021. It was reported that, all the symptoms essentially resolved after 96 hours from dose. Patient did not received any treatment for events. The outcome of all the events were recovered on an unknown date in 2021.  No follow-up attempts are possible. No further information is expected.
Information has been received from a pharmacist concerning an 80 year old healthy female who on June 14 2004 was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine. There was no concomitant vaccines given. It was reported that the patient was hospitalized with gastrointestinal bleeding at the time of vaccination. About two hours after the injection the patient experienced an injection site reaction described as a red, swollen and itching arm, Medical attention was sought, but no treatment was required. No product quality complaint was involved. Additional information has been requested.
Client had previously received Moderna Dose 1. Client received separate invite for Janssen due to signing up twice and they came in. Previous Moderna dose not caught in clinic and Janssen dose given incorrectly. Client does not need any additional COVID vaccine.
Pain, redness and swelling at the injection site; Pain, redness and swelling at the injection site; Pain, redness and swelling at the injection site; This spontaneous case was received on 28-Sep-2020 from other non-health professional via agency (reference number: SEQW20-02484) and concerned a 59-year old, female patient.   The patient's concurrent conditions included high blood pressure and high cholesterol. The patient's concomitant medications included doxycycline, losartan, atorvastatin, and escitalopram, all used for unreported indications.   On 26-Sep-2020, the patient was vaccinated with Flucelvax QIV (influenza vaccine, subunit influenza virus vaccine polyvalent; dose: 0.5 ml, expiry date, anatomical location and route of administration) for flu prophylaxis. The batch number reported was not reported.  On 27-Sep-2020, one day after vaccination, the patient experienced pain, redness and swelling at the injection site.   At the time of initial reporting on 28-Sep-2020, the patient had not recovered from events.  The reporter did not provide a causality assessment.  The reporter assessed the events as non-serious.  Company comment: The events of 'vaccination site pain', 'vaccination site erythema' and 'vaccination site swelling' are considered as related to Flucelvax QIV.; Sender's Comments: The events of 'vaccination site pain', 'vaccination site erythema' and 'vaccination site swelling' are considered as related to Flucelvax QIV.
Shot was received and patient said now she has a rash around the area was the shot was administered. no significant swelling, itching. just a visible rash that has spread around the shoulder.
RAPID HEART RATE; DIZZINESS; UNABLE TO MOVE; MUSCLE ACHES; HEADACHE; LEGS WOBBLING; This spontaneous report received from a patient concerned an 83 year old female. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown, and batch number: 6043A21A expiry: UNKNOWN) dose was not reported, administered on 06-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 06-APR-2021, the subject experienced legs wobbling. On an unspecified date, the subject experienced rapid heart rate, dizziness, unable to move, muscle aches, and headache. Laboratory data (dates unspecified) included: X-ray (NR: not provided) not related to symptoms. Treatment medications (dates unspecified) included: acetylsalicylic acid, and paracetamol. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the muscle aches, dizziness, headache, rapid heart rate, legs wobbling and unable to move was not reported. This report was non-serious.; Sender's Comments: V0: Medical assessment comment not required as per the standard operating procedure as the case is assessed as non-serious.
Patient was supposed to receive Hep B vaccination final dose in series but was accidentally given the pediatric HIB vaccination.
tiredness; chills; muscle pain; fever that comes and goes; Feeling of being Unwell; pain at the injections site; This is a spontaneous report from a contactable consumer (patient). A 72-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot Number: EN6200; Expiration Date: 30Jun2021), via an unspecified route of administration in left arm on 01Mar2021 (at the age of 72-year-old) as dose 1, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. Caller received first vaccine on 01Mar2021 and clarified first vaccine was Pfizer Covid vaccine. He had pain for first 24 hours at the injection site and has gone away. He states it was gone. Caller reported having tiredness, fever that comes and goes, chills, a feeling of being unwell and muscles pain still after 8 days. Caller asked if this was to be expected from the vaccine or was something wrong with his vaccine. Caller continues to state the tiredness was most of the concern and the feeling of being unwell. Caller wanted to know if this was going to last 20-30 days and wanted information for duration of side effects after one dose instead of two doses that was provided. Caller was concerned about getting the second dose of the COVID 19 vaccine because his side effects have lasted 7 days continuous. The outcome of injection site pain was resolved on 02Mar2021 and rest of all events was reported as not resolved.   No follow up attempts are possible. No further information is expected.
This case was reported by a nurse and described the occurrence of decreased movement of the arm in a 26 year old female patient who received hepatitis B vaccine recombinant (Engerix-B). On 16 November 2004, the patient received an injection of influenza virus vaccine (Fluzone). On 28 December 2004, the patient received the second dose of Engerix-B in the left arm (lot AHBVB034BB). At an unspecified time following the second dose of Engerix-B, on 28 December 2004, the patient experienced "reduced movement" of the left arm, a fever of 98.8 degrees Fahrenheit, and an injection site reaction characterized as soreness and warmth. The patient was seen at a physician's office. The events resolved on 04 January 2005.
Pt admit to hospital 10/7/21, COVID positive - s/p 2 doses of Pfizer (last dose 2/26/21)
Moderate reaction, Soreness, swelling, hard bump at injection site, size of  quarter, redness, heat around bump size of baseball.  Redness decreasing on day 6, bump nd soreness still present
devel knot size of palm of hand w/2" red hand below it-talked w/MD who advised heat & DPH cleared p/2days
This spontaneous report as received from a medical assistant refers to an unspecified number of patients of unknown age and gender. There was no information about the patients' concurrent conditions, concomitant therapies or medical histories provided. On unknown dates, the patients were vaccinated with improperly stored doses of VARIVAX lot # M037642, expiration date 01-SEP-2018 (dose and route of administration were not reported). There were no adverse effects reported. Administered doses of vaccines experienced the temperature excursions of: -12.3 degrees Celsius (-14 degrees Celsius to -10 degrees Celsius range) for 1 hour 49 minutes; >-15 degrees Celsius but <-10 Celsius range for 7 hours 14 minutes; >-10 degrees Celsius but <8 Celsius range for 2 hours 38 minutes. Data logger was involved. Additional information has been requested.
Extreme bodily pain all over, fever not exceeding 101,  chills, responded to Tylenol, lasted about 24 hours.
Patient reports after he received vaccine he started having dizziness, and pressure on left side of chest. Patient reports he received Pfizer vaccine at pharmacy. Patient was seen at this clinic today with left sided chest pain
SWELLING SIZE OF SILVER DOLLAR, PAIN, REDNESS, TENDER TO TOUCH, FELT LIKE BEE STING UPON INJECTION
Administered Tdap and Meningitis vaccine (R) deltoid at Co. Health Dept. On 9/3/15 mother brought child in with c/o red, warm and painful injection site. Went to urgent care and given KEFLEX for 7 days on 9/3/15 after office visit with me.
Patient received the vaccine and was asked to wait in the observation area afterwards.  He approached the counter a few minutes later to report he wasn't feeling well.  As he was speaking with the technician he became very pale, reported lightheadedness and fainted with loss of consciousness.  The technician reported that he witnessed convulsive type tonic movements concentrated in the neck and upper-arms more than the abdomen or legs.  He also reported foaming at the mouth and following each event which repeated 3 times in less then 15 minutes,  he woke with confusion and no memory of where he was.  EMS arrived after 15 minutes and transported the patient to the ED for evaluation.    Upon follow up with the patient the next day, he reported that the ED found nothing on his medical exam and he had worked a 10 hour shift prior to receiving the vaccine and had had nothing to eat or drink.
sent to emergency room due to left sided weakness, had a seizure upon arrival to er---MRI/MRA revealed Right MCA stroke.
5 March 2021   1:11pm second dose Moderna Vaccine  6:30pm minor soreness at injection site left upper shoulder  2 inches down from shoulder joint near injection site  8:11pm temperature 97.1 F soreness at injection site   6 March 2021  7:45am Temperature 97.3 F soreness in left upper arm localized in the deltoid muscle  11:49am increased myalgia and fatigue,  soreness in left upper arm localized in the deltoid muscle  1:13pm Temp 98.8 F and increased myalgia and fatigue, increased soreness in injection site but limited to deltoid muscle.  5:46pm Temp. At 99.5 F and increased myalgia and fatigue, increased soreness in injection site but limited to deltoid muscle.  9:04pm temp at 98.9 symptoms same as previous  7 March 2021  9:20 AM Temperature 96.2 F myalgia reduced to pre-vaccination level and soreness only at injection site  8 March 2021  11:45 am temperature 98.0 myalgia reduced to pre-vaccination level and minor soreness at injection site  9 March 2021 All reactogenicity no longer present.
Red rash in the shape of an oval 5 by 3 inches around the site of injection. Not raised. Patient did not notice erythema until two weeks after shot. Patient also experience transient sore arm and fatigue.
Headache; Body aches; Metal taste in mouth; Rapid heart rate; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 08Apr2021 at 15:45 (at the age of 53-year-old), as a single dose for COVID-19 immunisation. Medical history included rapid heart rate, colitis and COVID-19. The patient did not have any history of allergies to medications, food, or other products. Concomitant medications included meloxicam (MELOXICAN) and metoprolol (MANUFACTURER UNKNOWN) from an unknown date for an unspecified indication. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021 few minutes after the vaccination, the patient experienced a metal taste in mouth, later that evening patient had a rapid heart rate and patient felt terrible. On 08Apr2021 at 10:00, the patient had a headache and body aches. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken for the events. The clinical outcome of the events metal taste in mouth, rapid heart rate, head ache and body aches were recovered on an unknown date in Apr2021.  No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.